↓ Skip to main content

Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases

Overview of attention for article published in Cytometry Part B: Clinical Cytometry, July 2015
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
52 Dimensions

Readers on

mendeley
87 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases
Published in
Cytometry Part B: Clinical Cytometry, July 2015
DOI 10.1002/cyto.b.21269
Pubmed ID
Authors

Fanny Pojero, Juan Flores‐Montero, Luzalba Sanoja, José Juan Pérez, Noemí Puig, Bruno Paiva, Sebastian Bottcher, Jacques J. M. van Dongen, Alberto Orfao, on behalf of the EuroFlow group

Abstract

Multiparameter flow cytometry (MFC) identification and characterization of plasma cells (PC) is a useful tool to support diagnosis, prognostication and monitoring of PC diseases (PCD). Currently, the number of MFC markers suited for the identification of PC remains limited. Moreover, antibody therapies against PC-associated markers further compromise the utility of the most widely used reagents (e.g. CD38). Despite markers other than CD38 and CD138 are recognized as potentially useful PC-identification markers, no study has comparatively evaluated their performance in combination with CD38 and CD138. Here we compared the utility of CD229, CD54 and CD319 for the identification of normal and aberrant PC. Bone marrow samples from 5 healthy controls, two non-infiltrated non-Hodgkin lymphoma cases and 46 PCD patients plus 3 extraosseous plasmocytomas, plus normal PB specimens, were studied. Our results showed adequate performance of all three markers once combined with CD38. In contrast, when combined with CD138 for the identification of PC, only CD229 provided a good discrimination between PC and all other cells in the sample for all BM and PB samples analyzed; in contrast, CD54 and CD319 showed limited utility for the identification of PC, mainly because of significant overlap of the staining for these two markers on PC and other myeloid cells in the sample. From the three markers evaluated, CD229 may be considered as the most reliable marker to replace CD38 or CD138 for the identification of PCs in patients undergoing anti-CD38 or anti-CD138 therapy, until a better alternative is available. This article is protected by copyright. All rights reserved.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Denmark 2 2%
Spain 1 1%
United Kingdom 1 1%
Unknown 83 95%

Demographic breakdown

Readers by professional status Count As %
Other 19 22%
Researcher 18 21%
Student > Master 9 10%
Student > Ph. D. Student 7 8%
Student > Postgraduate 7 8%
Other 10 11%
Unknown 17 20%
Readers by discipline Count As %
Medicine and Dentistry 25 29%
Biochemistry, Genetics and Molecular Biology 15 17%
Agricultural and Biological Sciences 12 14%
Immunology and Microbiology 11 13%
Nursing and Health Professions 2 2%
Other 2 2%
Unknown 20 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 July 2015.
All research outputs
#20,656,161
of 25,374,647 outputs
Outputs from Cytometry Part B: Clinical Cytometry
#453
of 597 outputs
Outputs of similar age
#201,260
of 275,156 outputs
Outputs of similar age from Cytometry Part B: Clinical Cytometry
#11
of 16 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 597 research outputs from this source. They receive a mean Attention Score of 3.7. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 275,156 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.